Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers

Caroline Holm Nørgaard, Sarah Friedrich, Charlotte Thim Hansen, Thomas Gerds, Clive Ballard, Daniel Vega Møller, Lotte Bjerre Knudsen, Kajsa Kvist, Bernard Zinman, Ellen Holm, Christian Torp-Pedersen, Lina Steinrud Mørch

Abstract

Introduction: People with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes.

Methods: We assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients).

Results: Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs).

Discussion: Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.

OriginalsprogEngelsk
Artikelnummere12268
TidsskriftAlzheimer's & Dementia: Translational Research & Clinical Interventions
Vol/bind8
Udgave nummer1
Sider (fra-til)e12268
ISSN2352-8737
DOI
StatusUdgivet - 2022

Fingeraftryk

Dyk ned i forskningsemnerne om 'Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers'. Sammen danner de et unikt fingeraftryk.

Citationsformater